KPV research roundup — September 2026
A live literature check this month found two new preclinical KPV studies — an oral delivery conjugate tested in colitis and acute lung injury, and a melanocyte-targeted liposome tested in a vitiligo model — and confirmed, again, that no human trial of KPV exists. What the new work does and does not show, and where the full evidence record lives.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), studied mainly in rodent models of gut inflammation and in keratinocyte or melanocyte cell culture. The full study list — every paper, its model and what it found — lives at the compound's research entry and is not repeated here.
This post is dated commentary for researchers and laboratory personnel tracking the literature: what a fresh search of PubMed and ClinicalTrials.gov turned up this run, whether anything closed the human-data gap that has defined this compound's evidence base, and what the newest papers actually add.
Key takeaways
- A live PubMed check this run found two KPV studies published in 2026 that are not yet on the compound's research entry: an oral conjugate tested in colitis and, separately, acute lung injury, and a melanocyte-targeted liposome tested in a vitiligo model.
- Neither new study used free KPV the way it appears in a reconstituted vial — one used an engineered prodrug conjugate, the other used KPV as a targeting ligand on a liposome carrying a gene-silencing payload, not as the active anti-inflammatory agent itself.
- A live query of ClinicalTrials.gov this run returned zero registered studies naming KPV — the human-data gap is unchanged.
- The lung-injury and vitiligo findings widen the disease areas where KPV-based constructs are being tested; they do not extend the evidence for free KPV itself into those areas.
- No published study has assessed fatigue or tiredness as an outcome for KPV, in any model — the question has simply not been studied.
- The full study list, evidence-maturity rating and identifiers stay at /research/kpv; this page adds only what changed.
What a live literature check turned up this run
PubMed's E-utilities were queried this run for KPV restricted to 2026 publication dates and to records not already cited on the compound's research entry. Most 2026 hits mentioning KPV were reviews or unrelated studies that name it only in passing — a sports-medicine review of peptide doping and a pharmacy-compounding trade article both mention KPV as an example compound without presenting new findings about it. Two records were substantive, primary studies that actually used KPV.
The first, published online in Science Advances in January 2026, built an oral prodrug platform — a self-immolative peptide conjugate designed to survive the gut and release its payload at sites of inflammation. The authors tested a KPV-based version of the conjugate ("proKPV") in mice with colitis and separately in mice with acute lung injury, reporting 3.8-fold greater colonic accumulation than free KPV and effective doses roughly 20-fold lower than free peptide, with anti-inflammatory activity extending to the lung model as well as the gut.
The second, published in Cell Death & Differentiation in February 2026, is not primarily a KPV study at all: it investigates how a breakdown in the clearance of NLRP3 — a protein that triggers inflammation when it accumulates in a cell — contributes to vitiligo in melanocytes, the pigment-producing skin cells vitiligo affects. KPV appears as a delivery tool — the authors built "KPV-modified deformable liposomes" that use KPV's affinity for the melanocortin receptor on melanocytes to steer a gene-silencing payload (an Nlrp3 shRNA, a short synthetic RNA sequence designed to suppress that one gene) specifically into those cells, and knocking down NLRP3 that way reduced vitiligo progression in their mouse model.
What the new work does and does not show
Both papers are genuine additions to the KPV literature, and both are worth reading honestly for what they are rather than what a headline might imply. Neither administered free KPV — the tripeptide as it appears in a reconstituted vial — as the active therapeutic agent and measured its own anti-inflammatory effect the way the compound's existing colitis studies do.
The Science Advances paper's own efficacy comparison makes this explicit: the engineered conjugate outperformed free KPV in their model, which is a finding about the conjugate's pharmacokinetics — better gut stability, better site-specific release — not a new finding about free KPV's biology. The lung-injury result belongs to the same engineered molecule, not to the parent peptide.
The vitiligo paper is a step further removed again: KPV is not the therapeutic there at all. It is used the way a targeting antibody or a folate tag is used elsewhere in drug delivery — as an address label that gets a payload into the right cell type — and the reported benefit belongs to the Nlrp3 shRNA payload and the underlying autophagy mechanism the authors describe, not to any anti-inflammatory action of KPV itself.
Still no human data
The question searched most often alongside this compound's name is whether human studies exist. As of this run, they do not. A live query of ClinicalTrials.gov for "KPV" this run returned zero registered studies, matching every prior state of this compound's evidence base.
That gap sits under both of this run's new findings the same way it sits under the compound's existing gut-inflammation studies: everything published on KPV, including the newest work, is preclinical — rodent models, cell culture, or in this run's case, engineered delivery constructs tested in mice.
Does KPV peptide make you tired?
This is a frequently searched question, and the honest research answer is that it has not been studied. No published paper on KPV — not the gut-inflammation studies, not the keratinocyte work, not the two new 2026 papers covered above — measured fatigue, tiredness, sedation or any comparable subjective or behavioural endpoint. The traumatic-brain-injury study on the compound's research entry looked at brain inflammation and cell death markers after a single dose in mice, not at activity level or alertness.
Because no human trial of KPV exists at all, there is no human safety or tolerability data of any kind to draw on, fatigue included. "Not studied" is a different statement from "no effect" or "safe" — it means the literature is silent on this specific question, and anything more definite than that is not supported by what has actually been published.
Reading the field without overreading it
Coverage of KPV elsewhere sometimes treats a new delivery-technology paper as though it were new evidence that the plain peptide itself does more, or does it better, than the existing rodent colitis studies already show. Neither of this run's new papers does that: one improves how a KPV-based conjugate reaches inflamed tissue, and the other repurposes KPV's receptor affinity as a cell-targeting tool for a different active ingredient entirely.
The honest summary has not changed this run: KPV's own evidence base remains entirely preclinical, concentrated in gut inflammation and keratinocyte or melanocyte biology, with no human study of any kind and no study of fatigue or other subjective effects at any stage.
What would actually change the picture
A handful of concrete developments would move this compound's evidence rating; none has happened yet. These are the items worth checking a live registry or database for, rather than taking on trust from secondary coverage.
- 01
A registered human trial
A ClinicalTrials.gov (or equivalent regional registry) entry naming KPV, at any phase, would be the first concrete step — none exists as of this run.
- 02
A study of free KPV in a new disease area
This run's two new papers both used KPV as an engineered conjugate or a targeting ligand rather than as the free peptide; a study administering unmodified KPV itself in lung injury or a pigment-related condition would be the first direct evidence in those areas.
- 03
Any endpoint bearing on tolerability
Fatigue, alertness and other subjective or behavioural measures have not been assessed for KPV in any published model; a study that included one would be the first data point on this specific question.
- 04
Independent replication of the delivery-platform results
The oral-conjugate findings come from one laboratory group; replication of the accumulation and dose-reduction figures by an unaffiliated group would strengthen that specific result on its own terms.
Common questions.
- Is there kpv peptide research in human studies?
No. As of this check, no human trial of KPV has been published or registered. A live search of ClinicalTrials.gov this run returned zero studies naming KPV. Every published finding comes from rodent models, cell culture or, in the newest 2026 work, engineered delivery constructs tested in mice.
- Does kpv peptide make you tired?
No published study has measured fatigue, tiredness or a comparable endpoint for KPV, in any model. The compound's brain-injury study looked at inflammation and cell death after a single dose, not at alertness or activity level, and no human data exists at all. The literature is silent on this specific question rather than supporting an answer either way.
- What new kpv studies exist this year?
A live literature check this run found two 2026 papers not yet reflected on KPV's research entry: a Science Advances study using an engineered oral "proKPV" conjugate in mouse models of colitis and acute lung injury, and a Cell Death & Differentiation study using KPV as a melanocyte-targeting ligand on liposomes carrying a separate gene-silencing payload in a vitiligo model. Neither administered free KPV as the active therapeutic agent the way the compound's existing colitis studies do.
- How many kpv studies exist?
The full, individually cited list — with each study's model, tier and finding — is maintained at the compound's research entry rather than restated here, because that list changes independently of any single dated post. As of this run it remains entirely preclinical, with no human study among them.
Sources
- 01Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers — Cheng J, et al., Science Advances (2026), PMID 41533788
- 02NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development — Zeng K, et al., Cell Death & Differentiation (2026), PMID 40935835
- 03ClinicalTrials.gov search for "KPV" — 0 registered studies (checked live 2026-09-21)
- 04Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice — Schaible EV, et al., PLoS One (2013), PMID 23940690